J 2021

Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data

SINGH, A., Mohammad Salman HUSSAIN, R. JHA, A. S. JAYRAJ, Miloslav KLUGAR et. al.

Basic information

Original name

Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data

Authors

SINGH, A., Mohammad Salman HUSSAIN (356 India, belonging to the institution), R. JHA, A. S. JAYRAJ, Miloslav KLUGAR (203 Czech Republic, belonging to the institution) and B. ANTONY (guarantor)

Edition

JOURNAL OF EVIDENCE BASED MEDICINE, HOBOKEN, WILEY, 2021, 1756-5383

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30218 General and internal medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 6.224

RIV identification code

RIV/00216224:14110/21:00123257

Organization unit

Faculty of Medicine

DOI

UT WoS

000706758800001

Keywords in English

hepatocellular carcinoma; meta-analysis; pharmacoepidemiological study; proton pump inhibitors; real-world evidence; systematic review

Tags

Tags

International impact, Reviewed
Změněno: 1/2/2022 11:18, Mgr. Tereza Miškechová

Abstract

V originále

Proton pump inhibitors (PPIs) were first introduced in the market in the 1980s and are used as an over-the-counter (OTC) drug for acid-related diseases of the gastrointestinal tract. (1) Over the years, both prescription and non-prescription use of PPIs has grown exponentially, and they are now among the most widely used class of drugs globally. (2) PPIs are generally intended for short-term use and are rarely required beyond four to eight weeks; however, in real-world practice, their duration of use often extends beyond recommended guidelines. Hepatocellular carcinoma (HCC), a primary liver cancer, is a heterogeneous disease with multiple variables that differ by geography and presence or absence of prognostic factors such as NAFLD and cirrhosis. Preclinical studies have found PPIs-induced acid suppression to be associated with disease progression in hepatic diseases such as alcoholic liver disease, NAFLD, non-alcoholic steatohepatitis, and liver tumors. Similarly, population-based studies have also found an association of PPIs use with the risk of acute liver injury. (3) Nevertheless, many recent pharmacoepidemiologic studies using real-world databases to evaluate the association between PPIs and the risk of HCC show divergent results. (4-6) Thus, a systematic review was conducted to identify all the published articles and to determine the effect of PPI on the risk of HCC based on real-world data studies.